
TABLE OF CONTENTS

HEADS OF AGENCIES – CMDH.....	1
HEADS OF AGENCIES – PAEDIATRIC REGULATION	2
EUROPEAN MEDICINES AGENCY (EMA)	2
NOTICE TO APPLICANTS.....	12
BFARM - PHARMAKOVIGILANZ (SPECIFIC FOR GERMANY)	12
BFARM – MEDIZINPRODUKTE (SPECIFIC FOR GERMANY)	13
PEI - VIGILANZ (SPECIFIC FOR GERMANY)	13
PHARMEUROPA TEXTS FOR COMMENT.....	13

HEADS OF AGENCIES – CMDh

03 July

[NEW - Summary ARs for doxazosin mesylate/finasteride](#)

[UPDATE - DCP D70 Overview AR template \(incl. instructions\)](#)

[UPDATE - DCP D70 Overview AR template \(empty\)](#)

[UPDATE - Instructions for RMS when preparing the PAR based on the FAR](#)

[UPDATE - PAR template \(empty\) when prepared based on FAR](#)

[UPDATE - Post-Brexit Q&A](#)

[UPDATE - Q&A on QP Declaration](#)

[UPDATE - Q&A on variations](#)

[UPDATE - BPG for the allocation of the MRP variation number for Type I notifications, Type II variations, grouping and worksharing \(Chapter 1\)](#)

[UPDATE - BPG for the processing of Type IA minor variations \(notifications\) in MRP \(Chapter 3\)](#)

[UPDATE - BPG for the processing of grouped applications in MRP \(Chapter 6\)](#)

[UPDATE - BPG on Variation Worksharing \(Chapter 7\)](#)

[UPDATE - Cover letter for variation applications in MRP](#)

[UPDATE - BPG on the use of eCTD in the MRP/DCP](#)

[UPDATE - Requirements on submissions for Variations and Renewals within MRP and National Procedures](#)

01 July

[NEW - Report from the meeting held on 23-25 June 2026](#)

30 June

[NEW - 19-20 May CMDh Minutes](#)

[NEW - Presentations from the 25 June 2026 meeting with Interested Parties](#)

HEADS OF AGENCIES – PAEDIATRIC REGULATION

Article 45 work-sharing: [click here](#)

EUROPEAN MEDICINES AGENCY (EMA)

Date	Content	Status
03/07/2026	Medicine: Rexatilux ranibizumab	Updated
03/07/2026	PIP: EMA/PE/0000234516 - paediatric investigation plan quemliclustat	New
03/07/2026	PIP: EMA/PE/0000230610 - paediatric investigation plan cetrelimab	New
03/07/2026	PIP: EMA/PE/0000238858 - paediatric investigation plan acetylsalicylic acid; rivaroxaban	New
03/07/2026	PIP: EMA/PE/0000182225 - paediatric investigation plan eneboparatide	New
03/07/2026	PIP: EMA/PE/0000237903 - paediatric investigation plan padeliporfin di-potassium	New
03/07/2026	PIP: EMA/PE/0000239753 - paediatric investigation plan maridebart cafraglutide	New
03/07/2026	Medicine: Redemplo plozasiran	Updated
03/07/2026	Medicine: Retsevm selpercatinib	Updated
03/07/2026	Medicine: Pyzchiva ustekinumab	Updated
03/07/2026	Medicine: Opuviz afibercept	Updated
03/07/2026	Medicine: Cejemly sugemalimab	Updated
03/07/2026	Medicine: Kesimpta ofatumumab	Updated
03/07/2026	Medicine: Lorviqua lorlatinib	Updated

Date	Content	Status
03/07/2026	PIP: EMA/PE/0000229973 - paediatric investigation plan fosigotifator sodium tromethamine	Updated
03/07/2026	Medicine: Zegalogue dasiglucagon	Updated
03/07/2026	PIP: EMA/PE/0000227014 - paediatric investigation plan baxdrostat	New
03/07/2026	PIP: EMA/PE/0000230592 - paediatric investigation plan gemcitabine hydrochloride	New
03/07/2026	PIP: EMA/PE/0000242035 - paediatric investigation plan puxitatur samroscan	New
03/07/2026	PIP: EMA/PE/0000234339 - paediatric investigation plan SARS-CoV-2, spike protein, recombinant, expressed in Sf9 cells derived from Spodoptera frugiperda	Updated
03/07/2026	PIP: EMA/PE/0000237724 - paediatric investigation plan pimicotinib hydrochloride hydrate	Updated
03/07/2026	PIP: EMA/PE/0000237224 - paediatric investigation plan ocrelizumab	Updated
03/07/2026	PIP: EMA/PE/0000228372 - paediatric investigation plan borrelia outer surface protein A (OspA) serotypes (ST1-6) lipidated, fusion protein vaccine	Updated
03/07/2026	PIP: EMA/PE/0000237559 - paediatric investigation plan azilsartan medoxomil	Updated
03/07/2026	PIP: EMA/PE/0000235999 - paediatric investigation plan finerenone	Updated
03/07/2026	Event: Workshop on the use of external controls for evidence generation in regulatory decision-making	Updated
03/07/2026	PIP: EMA/PE/0000235991 - paediatric investigation plan etimumotide; imsamotide	New
03/07/2026	PIP: EMA/PE/0000238063 - paediatric investigation plan taladegib	New
03/07/2026	PIP: EMA/PE/0000238632 - paediatric investigation plan avalglucosidase alfa	Updated
03/07/2026	Page: Variations requiring assessment (veterinary medicines)	Updated
03/07/2026	Event: Joint European Commission (EC) / European Medicines Agency (EMA) multi-stakeholder workshop on regulatory sandbox	New

Date	Content	Status
03/07/2026	PIP: EMA/PE/0000226763 - paediatric investigation plan tofacitinib citrate	Updated
03/07/2026	Event: Meeting of the HMA-EMA group focused on AI with industry stakeholders - June 2026	New
03/07/2026	PIP: EMA/PE/0000236669 - paediatric investigation plan ritilecitinib	Updated
03/07/2026	Document: List of clinical evaluation consultation procedure (CECP) opinions issued for medical devices awaiting finalisation of conformity assessment	Updated
03/07/2026	Medicine: Duvyzat givinostat	Updated
03/07/2026	PIP: EMA/PE/0000238977 - paediatric investigation plan eubacterial spores, purified from allogeneic faecal donations	Updated
03/07/2026	PIP: EMEA-003002-PIP04-23 - paediatric investigation plan avenciguat	New
03/07/2026	Page: Combination Products Operational Group: agendas and highlight reports	Updated
03/07/2026	PIP: EMEA-002183-PIP03-23 - paediatric investigation plan imlifidase	New
03/07/2026	Medicine: NeoRecormon epoetin beta	Updated
03/07/2026	PIP: EMA/PE/0000229606 - paediatric investigation plan Deferoxamine (mesylate); histidine; tryptophan; aspartic acid; n-acetyl-histidine (monohydrate); glycine; arginine; potassium chloride; calcium chloride (dihydrate); sodium chloride; alanine; 3,4-dimethoxy-N-methylbenzohydroxamic; magnesium chloride hexahydrate; L-tryptophan; oxogluric acid; n-hydroxy-3	Updated
03/07/2026	PIP: EMA/PE/0000232894 - paediatric investigation plan adeno-associated viral vector serotype 9 containing the human MECP2 gene	New
03/07/2026	Medicine: Advagraf tacrolimus	Updated
03/07/2026	PIP: EMA/PE/0000232776 - paediatric investigation plan lunsekimig	New
03/07/2026	Event: Clinical Trials Information System (CTIS): Information day	Updated

Date	Content	Status
03/07/2026	PIP: EMA/PE/0000228536 - paediatric investigation plan enlicitide (decanoate)	Updated
03/07/2026	Shortage: Tegsedi inotersen	New
03/07/2026	Document: Medicine shortage communication (MSC): TEGSEDI® (inotersen sodium, 284 mg solution for injection in prefilled syringe): planned marketing cessation (discontinuation)	New
03/07/2026	PIP: EMA/PE/0000238070 - paediatric investigation plan [4-(Methyl-1H-pyrazol-4-yl)-benzyl]-(6[7-(3-pyrrolidin-1-yl-propoxy)-imidazo[1,2-a]pyridin-3-yl]-pyrimidin-4-yl]-amine	New
03/07/2026	PIP: EMA/PE/0000237220 - paediatric investigation plan rezafungin acetate	Updated
03/07/2026	PIP: EMA/PE/0000236239 - paediatric investigation plan empasiprubart	New
03/07/2026	PIP: EMA/PE/0000228512 - paediatric investigation plan satralizumab	Updated
02/07/2026	PIP: EMA/PE/0000232757 - paediatric investigation plan sonelokimab	New
02/07/2026	PIP: EMA/PE/0000182928 - paediatric investigation plan propranolol hydrochloride	New
02/07/2026	PIP: EMEA-003489-PIP01-23 - paediatric investigation plan sonrotoclax	New
02/07/2026	PIP: EMEA-003489-PIP02-23 - paediatric investigation plan sonrotoclax	New
02/07/2026	PIP: EMEA-003435-PIP02-23 - paediatric investigation plan allogeneic faecal microbiota, pooled (MaaT013)	New
02/07/2026	PIP: EMA/PE/0000232774 - paediatric investigation plan 7-fluoro-1-isopropyl-3-methyl-8-(6-(3-(piperidin-1-yl)propoxy)pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (AZD1390)	New
02/07/2026	Medicine: Aquipta atogepant	Updated
02/07/2026	Medicine: Suliqua insulin glargine; lixisenatide	Updated
02/07/2026	Medicine: Xtandi enzalutamide	Updated
02/07/2026	News: EMA steps up efforts on medicines for women's health	New

Date	Content	Status
02/07/2026	Medicine: Xofluza baloxavir marboxil	Updated
02/07/2026	Medicine: Trimbow beclometasone; formoterol; glycopyrronium bromide	Updated
02/07/2026	Medicine: Lunsumio mosunetuzumab	Updated
02/07/2026	Medicine: Alkindi hydrocortisone	Updated
02/07/2026	Document: Declaration of interests: Silvy da Rocha Dias	Updated
02/07/2026	Document: Declaration of interests: Virginia Rojo Guerra	Updated
02/07/2026	PIP: EMA/PE/0000233398 - paediatric investigation plan fenfluramine hydrochloride	Updated
02/07/2026	PIP: EMA/PE/0000229605 - paediatric investigation plan ravulizumab	Updated
02/07/2026	Document: Highlight report - Combination Products Operational Group (COMBO) - In Vitro Diagnostics stream - June 2026	New
02/07/2026	Document: Organisation chart: Information Management	Updated
02/07/2026	Medicine: Elaprase idursulfase	Updated
01/07/2026	PIP: EMA/PE/0000235658 - paediatric investigation plan asundexian	Updated
01/07/2026	PIP: EMA/PE/0000240018 - paediatric investigation plan tezepelumab	Updated
01/07/2026	PIP: EMA/PE/0000232302 - paediatric investigation plan filgotinib maleate	Updated
01/07/2026	PIP: EMA/PE/0000224087 - paediatric investigation plan vosoritide	Updated
01/07/2026	PIP: EMA/PE/0000233864 - paediatric investigation plan Daridorexant	Updated
01/07/2026	Medicine: Ontozry cenobamate	Updated
01/07/2026	Medicine: Ondibta insulin glargine	Updated

Date	Content	Status
01/07/2026	Medicine: Hetronifly serplulimab	Updated
01/07/2026	Medicine: Gotenfia golimumab	Updated
01/07/2026	Medicine: Eydenzelt aflibercept	Updated
01/07/2026	Medicine: Zypadhera olanzapine	Updated
01/07/2026	Medicine: Braftovi encorafenib	Updated
01/07/2026	Medicine: Ztalmy ganaxolone	Updated
01/07/2026	Medicine: Teriflunomide Viatris (previously Teriflunomide Mylan) teriflunomide	Updated
01/07/2026	Document: Table of decisions of labelling exemption requests falling under article 63 of Directive 2001/83/EC examined by the Quality Review of Documents (QRD) Group	Updated
01/07/2026	Document: Timetable: Type IB variation requiring linguistic review	Updated
01/07/2026	Medicine: Koselugo selumetinib	Updated
01/07/2026	Medicine: Tenofovir disoproxil Viatris (previously Tenofovir disoproxil Mylan) tenofovir disoproxil	Updated
01/07/2026	Document: Timetable: Periodic safety update report (PSUR) and PSUR single assessment (PSUSA) - Advanced therapy medicinal products (ATMPs)	Updated
01/07/2026	Document: Timetable: Periodic safety update report (PSUR) and PSUR single assessment (PSUSA)	Updated
01/07/2026	Medicine: Noxafil posaconazole	Updated
01/07/2026	Medicine: Wezenla ustekinumab	Updated
01/07/2026	Document: List of centrally authorised products with safety-related changes to the product information	Updated

Date	Content	Status
01/07/2026	PIP: EMA/PE/0000232765 - paediatric investigation plan sargramostim	New
01/07/2026	Document: Timetable: Post-authorisation safety study (PASS) protocols and final results	Updated
01/07/2026	PIP: EMA/PE/0000232762 - paediatric investigation plan frexalimab	New
01/07/2026	PIP: EMA/PE/0000232758 - paediatric investigation plan remibrutinib	New
01/07/2026	PIP: EMA/PE/0000229486 - paediatric investigation plan histidine; tryptophan; aspartic acid; n-acetyl-histidine (monohydrate); glycine; alpha-ketoglutaric acid; arginine; potassium chloride; calcium chloride (dihydrate); sodium chloride; alanine; 3,4-dimethoxy-N-methylbenzohydroxamic acid (Custodiol-N); magnesium chloride hexahydrate	Updated
01/07/2026	Document: List of European Union reference dates (EURD) and frequency of submission of periodic safety update reports (PSURs)	Updated
01/07/2026	PIP: EMA/PE/0000227151 - paediatric investigation plan vidofludimus calcium	New
01/07/2026	PIP: EMA/PE/0000239193 - paediatric investigation plan hafnium oxide	New
01/07/2026	PIP: EMA/PE/0000228269 - paediatric investigation plan garetosmab	Updated
01/07/2026	PIP: EMA/PE/0000235857 - paediatric investigation plan bupivacaine	Updated
01/07/2026	Medicine: Keytruda pembrolizumab	Updated
01/07/2026	PIP: EMA/PE/0000237870 - paediatric investigation plan senaparib	New
01/07/2026	PIP: EMA/PE/0000229480 - paediatric investigation plan ianalumab	Updated
01/07/2026	Medicine: Mupleo (previously Lusutrombopag Shionogi) lusutrombopag	Updated
01/07/2026	Medicine: Erelzi etanercept	Updated
01/07/2026	Page: Plasma master file certificates	Updated

Date	Content	Status
01/07/2026	Medicine: Stocrin efavirenz	Updated
30/06/2026	Medicine: Comirnaty COVID-19 mRNA vaccine	Updated
30/06/2026	Medicine: Spikevax (previously COVID-19 Vaccine Moderna) COVID-19 mRNA vaccine	Updated
30/06/2026	Page: PRIME: priority medicines	Updated
30/06/2026	Document: European Medicines Agency Guidance for applicants seeking access to PRIME scheme	Updated
30/06/2026	Medicine: Xgeva denosumab	Updated
30/06/2026	Medicine: Bopediat furosemide	Updated
30/06/2026	PIP: EMA/PE/0000234140 - paediatric investigation plan denecimig	Updated
30/06/2026	PIP: EMA/PE/0000237950 - paediatric investigation plan tirzepatide	Updated
30/06/2026	PIP: EMA/PE/0000238064 - paediatric investigation plan allogeneic bone marrow derived mesenchymal stromal cells, ex-vivo expanded (MC0518)	Updated
30/06/2026	PIP: EMA/PE/0000236274 - paediatric investigation plan lacosamide	Updated
30/06/2026	PIP: EMA/PE/0000241152 - paediatric investigation plan chlorprocaine hydrochloride	Updated
30/06/2026	Medicine: Sifrol pramipexole	Updated
30/06/2026	PIP: EMA/PE/0000261034 - paediatric investigation plan ponatinib	Updated
30/06/2026	Medicine: Opzelura ruxolitinib	Updated
30/06/2026	Shortage: Mycobutin (rifabutin)	New
30/06/2026	PIP: EMA/PE/0000238615 - paediatric investigation plan senaparib	New
30/06/2026	PIP: EMA/PE/0000234980 - paediatric investigation plan human IgG1 monoclonal antibody against prostate specific membrane antigen conjugated to opadotin	New

Date	Content	Status
30/06/2026	PIP: EMA/PE/0000184035 - paediatric investigation plan sarilumab	Updated
30/06/2026	PIP: EMA/PE/0000231022 - paediatric investigation plan meropenem trihydrate; vaborbactam	Updated
30/06/2026	PIP: EMA/PE/0000238610 - paediatric investigation plan senaparib	New
30/06/2026	PIP: EMA/PE/0000232761 - paediatric investigation plan etavopivat	New
30/06/2026	PIP: EMA-003385-PIP01-22 - paediatric investigation plan axatilimab	New
30/06/2026	Document: European Medicines Agency's data protection notice for use of Microsoft Intune for personal and corporate-owned devices	Updated
30/06/2026	Page: Financial management and budgetary reporting	Updated
30/06/2026	Event: Pharmacovigilance Risk Assessment Committee (PRAC): 4 - 7 May 2026	Updated
30/06/2026	Medicine: Iqirvo elaflibanor	Updated
30/06/2026	Event: Q&A clinic on Substance, Organisation, Referentials Management Services - April 2026	Updated
30/06/2026	Event: Q&A clinic on eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) service - April 2026	Updated
30/06/2026	Event: Q&A clinic on Substance, Organisation, Referentials Management Services - May 2026	Updated
30/06/2026	Event: Q&A clinic on Product Management Service (PMS) Product User Interface (PUI) and Application Programming Interface (API) - May 2026	Updated
30/06/2026	PIP: EMA/PE/0000236723 - paediatric investigation plan brigatinib	Updated
30/06/2026	Medicine: Pelgraz pegfilgrastim	Updated
30/06/2026	Medicine: Doptelet avatrombopag	Updated

Date	Content	Status
30/06/2026	Referral: Sodium oxybate-containing syrup and oral solution for alcohol dependence - referral sodium oxybate	Updated
30/06/2026	Referral: Ipidacrine-containing medicinal products - referral ipidacrine	Updated
30/06/2026	Event: Q&A clinic on eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) service - May 2026	Updated
30/06/2026	Event: Product Management Service (PMS) information day 2026	Updated
30/06/2026	Medicine: Avtozma tocilizumab	Updated
30/06/2026	Event: Multistakeholder workshop on women's health	New
30/06/2026	Document: Product Management Service (PMS) roadmap	Updated
29/06/2026	Document: Decision of EMA on adoption by analogy of Commission decision C(2026) 634 final of 5 February 2026 amending Decision C(2002) 98 fixing rates of daily subsistence allowances and ceilings for reimbursements of hotel expenses for missions outside EU	New
29/06/2026	Medicine: Iloperidone Vanda Pharmaceuticals iloperidone	Updated
29/06/2026	Medicine: Ibuprofen Gen.Orph ibuprofen	Updated
29/06/2026	Medicine: Dazublys trastuzumab	Updated
29/06/2026	Medicine: Reyataz atazanavir sulfate	Updated
29/06/2026	Document: Annual activity report 2024	Updated
29/06/2026	Medicine: Kaftrio ivacaftor; tezacaftor; elexacaftor	Updated
29/06/2026	Medicine: Lytenava bevacizumab	Updated
29/06/2026	Medicine: Rekovelle follitropin delta	Updated
29/06/2026	Medicine: Mirapexin pramipexole	Updated

Date	Content	Status
29/06/2026	Event: Quarterly System Demo - Q2 2026	Updated
29/06/2026	Page: Class III implantable devices and Class IIb medical devices intended to administer or remove medicinal products: expert panel opinions	Updated
29/06/2026	Document: CAT quarterly highlights and approved ATMPs - June 2026	New
29/06/2026	Page: Annual reports and work programmes	Updated
29/06/2026	Event: Meeting of the Medicine Shortages Single Point of Contact (SPOC) Working Party	Updated
29/06/2026	Event: Committee for Medicinal Products for Veterinary Use (CVMP): 14-16 April 2026	Updated
29/06/2026	Page: Clinical evaluation of antifungal agents for the treatment and prophylaxis invasive fungal disease - Scientific guideline	Updated
29/06/2026	Document: Concept paper on the revision of the guideline on the clinical evaluation of antifungal agents for the treatment and prophylaxis of invasive fungal disease	New
29/06/2026	Shortage: Topamax topiramate	New
29/06/2026	Document: Medicine shortage communication (MSC): Topamax, Topimax, Epitomax, Topamac supply shortage	New

NOTICE TO APPLICANTS

No updates since June 24th, 2026.

BFARM - PHARMAKOVIGILANZ (SPECIFIC FOR GERMANY)

Date	Title
01.07.2026	Tavneos (Avacopan): Überprüfung der Wirksamkeit aufgrund von Fragen zur Datenintegrität der Hauptstudie Wirkstoff: Avacopan Die Europäische Arzneimittel-Agentur (EMA) empfiehlt den Widerruf der Zulassung für Tavneos, da nicht mehr nachgewiesen ist, dass der Nutzen der Behandlung die Risiken überwiegt.

BFARM – MEDIZINPRODUKTE (SPECIFIC FOR GERMANY)

No updates since June 23rd, 2026.

PEI - VIGILANZ (SPECIFIC FOR GERMANY)

Date	Title
01.07.2026	Paul-Ehrlich-Institut gestattet Einfuhr von für den französischen Markt bestimmtem Palforzia 300 mg Pulver zum Einnehmen im Beutel mit mehrsprachiger Beschriftung

PHARMEUROPA TEXTS FOR COMMENT

	Group	Issue	Deadline
2.4.37. Apparent molar radioactivity of radiometal solutions for radiolabelling Reference number: PA/PH/Exp. 14/T (24) 42 ANP Text number: 20437 Direct link	14	38.3	2026-09-30
2.6.12. Microbiological examination of non-sterile products: microbial enumeration tests Reference number: PA/PH/Exp. 1/T (26) 5 ANP Text number: 20612 Direct link	1	38.3	2026-09-30
2.6.13. Microbiological examination of non-sterile products: test for specified micro-organisms Reference number: PA/PH/Exp. 1/T (26) 6 ANP Text number: 20613 Direct link	1	38.3	2026-09-30
2.8.13. Pesticide residues Reference number: PA/PH/Exp. PST/T (25) 2 ANP Text number: 20813 Direct link	PST	38.3	2026-09-30
2.9.27. Uniformity of delivered doses from multidose containers Reference number: PA/PH/Exp. 12/T (26) 2 ANP Text number: 20927 Direct link	12	38.3	2026-09-30
3.3.2. Materials based on plasticised poly(vinyl chloride) for containers for human blood and blood components Reference number: PA/PH/Exp. 16/T (25) 28 ANP Text number: 30302 Direct link	16	38.3	2026-09-30

3.3.9. Prefillable plastic syringes for liquid preparations for injection Reference number: PA/PH/Exp. 16/T (14) 21 ANP Text number: 30309 Direct link	16	38.3	2026-09-30
5.1.4. Microbiological quality of non-sterile pharmaceutical preparations and substances for pharmaceutical use Reference number: PA/PH/Exp. 1/T (26) 7 ANP Text number: 50104 Direct link	1	38.3	2026-09-30
Adipic acid Reference number: PA/PH/Exp. 10D/T (26) 25 ANP Text number: 1586 Direct link	10D	38.3	2026-09-30
Alectinib hydrochloride Reference number: PA/PH/Exp. P4/T (26) 13 ANP Text number: 3219 Direct link	P4	38.3	2026-09-30
Boldo leaf dry extract Reference number: PA/PH/Exp. 13B/T (26) 38 ANP Text number: 1816 Direct link	13B	38.3	2026-09-30
Cabazitaxel concentrate for infusion Reference number: PA/PH/Exp. 11/T (26) 20 ANP Text number: 3233 Direct link	11	38.3	2026-09-30
Cinacalcet Hydrochloride Reference number: PA/PH/Exp. 10C/T (26) 3 ANP Text number: 3100 Direct link	10C	38.3	2026-09-30
Cyproterone acetate Reference number: PA/PH/Exp. 10B/T (26) 48 ANP Text number: 1094 Direct link	10B	38.3	2026-09-30
Deferasirox Reference number: PA/PH/Exp. 17/T (26) 6 ANP Text number: 2933 Direct link	17	38.3	2026-09-30
Dexmedetomidine Reference number: PA/PH/Exp. 10A/T (25) 41 ANP Text number: 3215 Direct link	10A	38.3	2026-09-30

Diclofenac Diethylamine Reference number: PA/PH/Exp. 10D/T (26) 17 ANP Text number: 2792 Direct link	10D	38.3	2026-09-30
Dioscorea nipponica rhizome Reference number: PA/PH/Exp. TCM/T (26) 21 ANP Text number: 2890 Direct link	TCM	38.3	2026-09-30
Donepezil hydrochloride Reference number: PA/PH/Exp. 10A/T (26) 20 ANP Text number: 2582 Direct link	10A	38.3	2026-09-30
Ezetimibe Reference number: PA/PH/Exp. 10D/T (13) 54 ANP R2 Text number: 2767 Direct link	10D	38.3	2026-09-30
Fluoxetine hydrochloride Reference number: PA/PH/Exp. 10A/T (26) 23 ANP Text number: 1104 Direct link	10A	38.3	2026-09-30
Heparin calcium Reference number: PA/PH/Exp. 6/T (25) 29 ANP Text number: 0332 Direct link	6	38.3	2026-09-30
Heparin sodium Reference number: PA/PH/Exp. 6/T (25) 28 ANP Text number: 0333 Direct link	6	38.3	2026-09-30
Hydrocortisone Reference number: PA/PH/Exp. 10B/T (26) 33 ANP Text number: 0335 Direct link	10B	38.3	2026-09-30
Hypromellose acetate succinate Reference number: PA/PH/Exp. EXP/T (26) 4 ANP Text number: 3101 Direct link	CEL	38.3	2026-09-30
Ipratropium bromide monohydrate Reference number: PA/PH/Exp. 11/T (26) 43 ANP Text number: 0919 Direct link	11	38.3	2026-09-30
Lenalidomide capsules Reference number: PA/PH/Exp. 17/T (24) 6 ANP Text number: 3081 Direct link	17	38.3	2026-09-30

Lenalidomide hydrochloride capsules Reference number: PA/PH/Exp. 17/T (24) 7 ANP Text number: 3243 Direct link	17	38.3	2026-09-30
Lithium citrate tetrahydrate Reference number: PA/PH/Exp. 9/T (26) 16 ANP Text number: 0621 Direct link	9	38.3	2026-09-30
Macrogols Reference number: PA/PH/Exp. 13H/T (25) 59 ANP Text number: 1444 Direct link	13H	38.3	2026-09-30
Nutgrass galingale rhizome Reference number: PA/PH/Exp. TCM/T (26) 4 ANP Text number: 3263 Direct link	TCM	38.3	2026-09-30
Potassium citrate monohydrate Reference number: PA/PH/Exp. 9/T (26) 15 ANP Text number: 0400 Direct link	9	38.3	2026-09-30
Respiratory Syncytial Virus vaccine (rDNA) Reference number: PA/PH/Exp. 15/T (25) 8 ANP Text number: 3275 Direct link	15	38.3	2026-09-30
Riboflavin sodium phosphate hydrate Reference number: PA/PH/Exp. VIT/T (26) 11 ANP Text number: 0786 Direct link	VIT	38.3	2026-09-30
Sodium nitroprusside dihydrate Reference number: PA/PH/Exp. 9/T (26) 14 ANP Text number: 0565 Direct link	9	38.3	2026-09-30
Southern Schisandra fruit Reference number: PA/PH/Exp. TCM/T (25) 120 ANP Text number: 3266 Direct link	TCM	38.3	2026-09-30
Thiocolchicoside crystallised from ethanol Reference number: PA/PH/Exp. 11/T (26) 41 ANP Text number: 2896 Direct link	11	38.3	2026-09-30
Thiocolchicoside hydrate Reference number: PA/PH/Exp. 11/T (26) 40 ANP Text number: 2814 Direct link	11	38.3	2026-09-30

Vismodegib Reference number: PA/PH/Exp. P4/T (24) 34 ANP Text number: 3269 Direct link	P4	38.3	2026-09-30
Vismodegib capsules Reference number: PA/PH/Exp. P4/T (24) 35 ANP Text number: 3270 Direct link	P4	38.3	2026-09-30

Trotz regelmäßiger Aktualisierung und sorgfältiger Überwachung der Veröffentlichungen können wir keine Haftung oder Garantie für die Aktualität, Richtigkeit und Vollständigkeit der hier bereitgestellten Informationen übernehmen.
Dieser Newsletter enthält Links zu anderen Websites. Trotz sorgfältiger inhaltlicher Kontrolle übernehmen wir keine Haftung für die Inhalte externer Links. Für den Inhalt der verlinkten Seiten sind ausschließlich deren Betreiber verantwortlich.

Despite regular updating and careful monitoring of the publications, we cannot take any responsibility or guarantee for the topicality, correctness and completeness of the information provided here.
This Newsletter contains links to other websites. Despite careful control of the content we would like to point out that we are not liable for the contents of external web links. The editors of the respective websites are fully responsible for their contents.